Patents by Inventor Philippe Billiald

Philippe Billiald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES
    Publication number: 20230391869
    Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
    Type: Application
    Filed: May 12, 2023
    Publication date: December 7, 2023
    Inventors: Philippe BILLIALD, Martine JANDROT-PERRUS, Gilles AVENARD
  • Inhibition of platelet aggregation using anti-human GPVI antibodies
    Patent number: 11692033
    Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: July 4, 2023
    Assignees: Acticor Biotech, Université Paris Cité, Université Paris-XIII, Inserm (Institut National de la Santé et de la Recherche Médicale), Université Paris-Saclay
    Inventors: Philippe Billiald, Martine Jandrot-Perrus, Gilles Avenard
  • NOVEL ANTI-HUMAN GPVI ANTIBODIES AND USES THEREOF
    Publication number: 20200384106
    Abstract: The present invention relates to humanized anti-human GPVI antibodies and uses thereof.
    Type: Application
    Filed: August 20, 2020
    Publication date: December 10, 2020
    Inventors: Philippe BILLIALD, Martine JANDROT-PERRUS
  • Anti-human GPVI antibodies and uses thereof
    Patent number: 10842870
    Abstract: The present invention relates to humanized anti-human GPVI antibodies and uses thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: November 24, 2020
    Assignees: ACTICOR BIOTECH, UNIVERSITE DE PARIS, UNIVERSITÉ PARIS-XIII, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE PARIS-SACLAY
    Inventors: Philippe Billiald, Martine Jandrot-Perrus
  • INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES
    Publication number: 20190367608
    Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
    Type: Application
    Filed: February 2, 2018
    Publication date: December 5, 2019
    Applicants: Acticor Biotech, Université Paris Diderot - Paris 7, Université Paris-XIII, Nserm (Institut National de la Santé et de la Recherche Médicale), Université Paris-Sud 11
    Inventors: Philippe BILLIALD, Martine JANDROT-PERRUS, Gilles AVENARD
  • NOVEL ANTI-HUMAN GPVI ANTIBODIES AND USES THEREOF
    Publication number: 20180236071
    Abstract: The present invention relates to humanized anti-human GPVI antibodies and uses thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: August 23, 2018
    Inventors: Philippe BILLIALD, Martine JANDROT-PERRUS
  • Anti-glycoprotein VI scFv fragment for treatment of thrombosis
    Patent number: 9045540
    Abstract: The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly4Ser)3 peptide and followed by a “c-myc” flag, represented by SEQ ID NO:1. The invention also concerns functional variants of said scFv 9O12.2 fragment with identical heavy and light chains complementary determining regions 1, 2 and 3, and preferably humanized functional variants such as the humanized scFv fragments represented by SEQ ID NO:28 or SEQ ID NO:47. The invention also relates to nucleic acids encoding such a scFv fragment, expression vectors and host cells to produce such a scFv fragment, as well as therapeutic uses of such a scFv fragment.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: June 2, 2015
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Martine Jandrot-Perrus, Philippe Billiald, Julien Muzard
  • Anti-glycoprotein VI scFv fragment for treatment of thrombosis
    Patent number: 9045538
    Abstract: The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly4Ser)3 peptide and followed by a “c-myc” flag, represented by SEQ ID NO:1. The invention also concerns functional variants of said scFv 9O12.2 fragment with identical heavy and light chains complementary determining regions 1, 2 and 3, and preferably humanized functional variants such as the humanized scFv fragments represented by SEQ ID NO:28 or SEQ ID NO:47. The invention also relates to nucleic acids encoding such a scFv fragment, expression vectors and host cells to produce such a scFv fragment, as well as therapeutic uses of such a scFv fragment.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: June 2, 2015
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Martine Jandrot-Perrus, Philippe Billiald, Julien Muzard
  • ANTI-GLYCOPROTEIN VI SCFV FRAGMENT FOR TREATMENT OF THROMBOSIS
    Publication number: 20130189259
    Abstract: The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly4Ser)3 peptide and followed by a “c-myc” flag, represented by SEQ ID NO:1. The invention also concerns functional variants of said scFv 9O12.2 fragment with identical heavy and light chains complementary determining regions 1, 2 and 3, and preferably humanized functional variants such as the humanized scFv fragments represented by SEQ ID NO:28 or SEQ ID NO:47. The invention also relates to nucleic acids encoding such a scFv fragment, expression vectors and host cells to produce such a scFv fragment, as well as therapeutic uses of such a scFv fragment.
    Type: Application
    Filed: December 21, 2012
    Publication date: July 25, 2013
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Martine Jandrot-Perrus, Philippe Billiald, Julien Muzard
  • Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis
    Patent number: 8466258
    Abstract: The present invention relates to diagnostic imaging and in particular to the diagnostic imaging of fibrosis. More particularly, the present invention provides a polypeptides, cyclic polypeptides and pharmaceutical compositions suitable for the non-invasive visualization of fibrosis. The polypeptide of the invention may comprise an amino acid sequence consisting of: X1-X2-M-H-G-L-X7-L-X9-X10-D-E (SEQ ID NO: 1) wherein amino acid X1 is R, F or P; amino acid X2 is F or V; amino acid X7 is Q, H or L; amino acid X9 is W or G and amino acid X10 is A or D.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: June 18, 2013
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Universite Paris Diderot—Paris 7
    Inventors: Martine Jandrot-Perrus, Julien Muzard, Philippe Billiald, Dominique le Guludec, Laure Sarda, Alain Meulemans
  • ANTI-GLYCOPTROTEIN VI SCFV FRAGMENT FOR TREATMENT OF THROMBOSIS
    Publication number: 20110182899
    Abstract: The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly4Ser)3 peptide and followed by a “c-myc” flag, represented by SEQ ID NO:1. The invention also concerns functional variants of said scFv 9O12.2 fragment with identical heavy and light chains complementary determining regions 1, 2 and 3, and preferably humanized functional variants such as the humanized scFv fragments represented by SEQ ID NO:28 or SEQ ID NO:47. The invention also relates to nucleic acids encoding such a scFv fragment, expression vectors and host cells to produce such a scFv fragment, as well as therapeutic uses of such a scFv fragment.
    Type: Application
    Filed: October 26, 2007
    Publication date: July 28, 2011
    Inventors: Martine Jandrot-Perrus, Philippe Billiald, Julien Muzard
  • Polypeptides, Cyclic Polypeptides and Pharmaceutical Comprising Thereof for Non Invasive Specific Imaging of Fibrosis
    Publication number: 20100303724
    Abstract: The present invention relates to diagnostic imaging and in particular to the diagnostic imaging of fibrosis. More particularly, the present invention provides a polypeptides, cyclic polypeptides and pharmaceutical compositions suitable for the non-invasive visualization of fibrosis. The polypeptide of the invention may comprise an amino acid sequence consisting of: X1-X2-M-H-G-L-X7-L-X9-X10-D-E wherein amino acid X1 is R, F or P; amino acid X2 is F or V; amino acid X7 is Q, H or L; amino acid X9 is W or G and amino acid X10 is A or D.
    Type: Application
    Filed: December 11, 2008
    Publication date: December 2, 2010
    Applicant: UNIVERSITE PARIS DIDEROT - PARIS 7
    Inventors: Martine Jandrot-Perrus, Julien Muzard, Philippe Billiald, Dominique le Guludec, Laure Sarda, Alain Meulemans